Expertise in
8
conditions

Lijie M. Tan

No. 180, Fenglin Road, 
Xuhui, CN 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
8
conditions
No. 180, Fenglin Road, 
Xuhui, CN 

Overview

Lijie Tan practices practicing medicine in Xuhui, China.

Tan is highly rated in 8 conditions, according to our data. Their clinical expertise encompasses Esophageal Cancer, Thymic Epithelial Tumor, Pneumomediastinum, Thymectomy, and Endoscopy.

They are actively involved in clinical research, co-authoring 244 peer reviewed articles and participating in 2 clinical trials.

Locations

No. 180, Fenglin Road, Xuhui, 200032, China
Other Locations
180 Fenglin Road, Zhongshan, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Multicenter Randomized, Controlled Phase III Clinical Trial of Pembrolizumab Plus Paclitaxel and Cisplatin Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma (KEYSTONE-002)
A Multicenter Randomized, Controlled Phase III Clinical Trial of Pembrolizumab Plus Paclitaxel and Cisplatin Versus Neoadjuvant Chemoradiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma (KEYSTONE-002)
Enrollment Status: Recruiting
Publish Date: June 01, 2022
Intervention Type: Biological, Radiation, Drug
Study Drugs: Pembrolizumab, Paclitaxel, Cisplatin
Study Phase: Phase 3
Neoadjuvant Chemoradiotherapy VS. Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0):A Multi-center Prospective Randomized Clinical Trial
Neoadjuvant Chemoradiotherapy VS. Neoadjuvant Chemotherapy Followed by Minimally Invasive Esophagectomy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma（cT3-4aN0-1M0):A Multi-center Prospective Randomized Clinical Trial
Enrollment Status: Completed
Publish Date: September 10, 2020
Intervention Type: Procedure
Study Phase: Not Applicable
View 1 Less Clinical Trial

244 Total Publications

Clinical characteristics and outcomes of pertussis encephalopathy in 17 children
Clinical characteristics and outcomes of pertussis encephalopathy in 17 children
Journal: Zhonghua er ke za zhi = Chinese journal of pediatrics
Published: February 12, 2026

Frequently Asked Questions about Lijie M. Tan

Is Lijie M. Tan a top-rated expert for Esophageal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Lijie M. Tan is classified as an Distinguished expert for Esophageal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Lijie M. Tan participate in research or clinical trials?

Yes. Lijie M. Tan has published 244 articles and abstracts on conditions like Esophageal Cancer. You can view a list of Lijie M. Tan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tan's expertise for a condition
ConditionClose
    View All 21 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile